Trial site
Toyohashi Municipal Hospital
Toyohashi, Aichi-ken 441-8570, JapanNot linked to an institution yet
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 38 trials
- Phase 1/21 trial
- Status
- Active, not recruiting6 trials
- Recruiting3 trials
- Lead sponsor
- Celgene2 trials
- Pfizer2 trials
- Abivax S.A.1 trial
- ADC Therapeutics S.A.1 trial
- BeOne Medicines1 trial
- and 2 more
Running trials
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· Phase 3· Bristol-Myers Squibb· Source
Contact: Yasushi Makino, Site 0055
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575· Phase 3· Pfizer· Source
Active, not recruiting
ABTECT - Maintenance
NCT05535946· Phase 3· Abivax S.A.· Source
Active, not recruiting
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414· Phase 3· Celgene· Source
Active, not recruiting
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484· Phase 3· ADC Therapeutics S.A.· Source
Active, not recruiting
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232· Phase 3· Pfizer· Source
Active, not recruiting
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297· Phase 3· BeOne Medicines· Source
Active, not recruiting
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
NCT02773030· Phase 1/2· Celgene· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error